SCHEMBL3517610

SCHEMBL3517610

COc1ccc(F)c(CN2CCOC(C(=O)N(Cc3ccc4c(c3)OCCCO4)CC(C)C)C2)c1

nearest known ligand 0.66

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PROKR2 Q8NFJ6 4/20 0.66
MTNR1B P49286 2/20 0.42
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
KDM4E B2RXH2 4/20 0.41
GLA P06280 1/20 0.39
MCHR1 Q99705 3/20 0.39
ALDH1A1 P00352 2/20 0.38
HSD17B10 Q99714 2/20 0.38
TSHR P16473 1/20 0.38
HTR1A P08908 1/20 0.37
SLC6A4 P31645 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3524424 1.00 PROKR2 (0.66) PROKR2MTNR1BKMT2AMEN1KDM4E
SCHEMBL3516797 0.98 PROKR2 (0.62) PROKR2MTNR1BKMT2AMEN1KDM4E
SCHEMBL3520413 0.92 PROKR2 (0.61) PROKR2MTNR1BKMT2AMEN1KDM4E
SCHEMBL3516611 0.92 PROKR2 (0.59) PROKR2KMT2AMEN1KDM4EGLA
SCHEMBL3520997 0.92 PROKR2 (0.64) PROKR2KMT2AMEN1KDM4EGLA
SCHEMBL20936059 0.90 PROKR2 (0.79) PROKR2MTNR1BKMT2AMEN1KDM4E
SCHEMBL3521599 0.89 PROKR2 (0.61) PROKR2KMT2AKDM4EMCHR1ALDH1A1
SCHEMBL3521885 0.88 PROKR2 (0.83) PROKR2KMT2AKDM4EGLAMCHR1
SCHEMBL3520056 0.88 PROKR2 (0.83) PROKR2KMT2AKDM4EGLAMCHR1
SCHEMBL3516871 0.88 PROKR2 (0.71) PROKR2KMT2AMEN1KDM4EMCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1959959-B1 MORPHOLINE CARBOXAMIDE PROKINETICIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2013-04-10 EP claimed
US-7855201-B2 Morpholine carboxamide prokineticin receptor antagonists Merck Sharp & Dohme. Corp. (US) 2010-12-21 US claimed
US-20090306076-A1 Morpholine Carboxamide Prokineticin Receptor Antagonists MERCK SHARP & DOHME LLC 2009-12-10 US claimed
EP-1959959-B1 MORPHOLINE CARBOXAMIDE PROKINETICIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2013-04-10 EP disclosed
US-7855201-B2 Morpholine carboxamide prokineticin receptor antagonists Merck Sharp & Dohme. Corp. (US) 2010-12-21 US disclosed
US-7855201-B2 Morpholine carboxamide prokineticin receptor antagonists Merck Sharp & Dohme. Corp. (US) 2010-12-21 US disclosed
US-7855201-B2 Morpholine carboxamide prokineticin receptor antagonists Merck Sharp & Dohme. Corp. (US) 2010-12-21 US disclosed
US-20090306076-A1 Morpholine Carboxamide Prokineticin Receptor Antagonists MERCK SHARP & DOHME LLC 2009-12-10 US disclosed
US-20090306076-A1 Morpholine Carboxamide Prokineticin Receptor Antagonists MERCK SHARP & DOHME LLC 2009-12-10 US disclosed
US-20090306076-A1 Morpholine Carboxamide Prokineticin Receptor Antagonists MERCK SHARP & DOHME LLC 2009-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306076-A1 Morpholine Carboxamide Prokineticin Receptor Antagonists PROKR2, PROKR1, NTSR2 PROKR2 1/4885MTNR1B 29/4885KMT2A 2847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.